Abstract
Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Protein & Peptide Letters
Title:Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation
Volume: 19 Issue: 9
Author(s): Yuko Tagaya, Aya Osaki, Atsuko Miura, Shuichi Okada, Kihachi Ohshima, Koshi Hashimoto, Masanobu Yamada, Tetsurou Satoh, Hiroyuki Shimizu and Masatomo Mori
Affiliation:
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Abstract: Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Export Options
About this article
Cite this article as:
Tagaya Yuko, Osaki Aya, Miura Atsuko, Okada Shuichi, Ohshima Kihachi, Hashimoto Koshi, Yamada Masanobu, Satoh Tetsurou, Shimizu Hiroyuki and Mori Masatomo, Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation, Protein & Peptide Letters 2012; 19 (9) . https://dx.doi.org/10.2174/092986612802084546
DOI https://dx.doi.org/10.2174/092986612802084546 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Capillary Electrophoresis–Mass Spectrometry in Metabolomics: The Potential for Driving Drug Discovery and Development
Current Drug Metabolism Resorcinol Derivatives as Novel Aldose Reductase Inhibitors: <i>In Silico</i> and <i>In Vitro</i> Evaluation
Letters in Drug Design & Discovery Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Application of Innate Immune Molecules for a New Class of Drugs: Infection, Inflammation and Beyond
Endocrine, Metabolic & Immune Disorders - Drug Targets Functional Imaging Combined with Multi-Detector CT: A Radionuclide Imaging Perspective
Current Medical Imaging Simultaneous Determination of Antidiabetic Thiazolidinediones Using Flow Through Voltammetric Sensor
Current Pharmaceutical Analysis Magnesium in Pain Research: State of the Art
Current Medicinal Chemistry Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design MicroRNAs in Arterial Hypertension
Current Topics in Medicinal Chemistry Heart Failure in Diabetes Mellitus: An Updated Review
Current Pharmaceutical Design Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19
Mini-Reviews in Medicinal Chemistry Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Monoclonal Antibodies to Treat Graft-Versus-Host Disease
Mini-Reviews in Medicinal Chemistry Retinol-Binding Protein 4 and New Adipocytokines in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Genetic Analysis of Gitelman Syndrome: Co-existence with Hyperthyroidism in a Two-year-old Boy
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry Novel Treatments of Schizophrenia: Targeting the Neurotensin System
CNS & Neurological Disorders - Drug Targets